

Open Peer Review on Qeios

BTK Inhibitor DTRMWXHS-12

National Cancer Institute

Source

National Cancer Institute. <u>BTK Inhibitor DTRMWXHS-12</u>. NCI Thesaurus. Code C130001.

An orally available inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, DTRMWXHS-12 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.

Qeios ID: 89ACVP · https://doi.org/10.32388/89ACVP